Soluble in DMSO or water
BQ-123 is an antagonist of endothelin receptors that has been shown to exhibit rapid reversibility. Research surrounding BQ-123 has focused heavily on its potential application as a novel anticancer drug, owing to its proven ability to inhibit binding of the overexpressed endothelin-1 that is associated with various cancers. Rat studies have provided in vivo evidence that BQ-123 can actively reduce tumor load. The compound has also been studied for its ability to affect ischemic arrhythmia in rat models. Intriguingly, the nature of this effect is highly dependent on dosage, with certain low dosages successfully attenuating arrhythmias and higher dosages actively exacerbating them.
Research or further manufacturing use only, not for food or drug use.